Europe Epigenetics Market

The report "Europe Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030" The global Europe epigenetics market is projected to reach USD 1.22 billion by 2030 from USD 0.63 billion in 2025, at a CAGR of 14.1% during the forecast period of 2025 to 2030. The Europe epigenetics market is growing, driven by sustained funding for life-science research and strong translational activity in oncology and precision medicine. Biopharma pipelines are increasingly using epigenetic biomarkers for target validation, patient stratification, and response monitoring. Wider adoption of multi-omics and single-cell research is driving higher demand for epigenetic profiling and downstream analytics. Growth is also supported by active cross-border research consortia and well-established core facilities that run high-throughput studies. An increasing focus on reproducible, standardized workflows is accelerating routine adoption across labs.

Browse 370 market data Tables and 42 Figures spread through 320 Pages and in-depth TOC on "Europe Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-epigenetics-market-252197128.html

The PCR & qPCR segment is expected to grow at the fastest rate during the forecast period.   

By technology, the epigenetics market in Europe is segmented into NGS, PCR & qPCR, mass spectrometry, sonication, and other technologies. The PCR & qPCR segment is expected to grow fastest during the forecast period, as users increasingly require rapid, cost-effective methods for methylation detection and biomarker validation. These platforms are well suited for targeted assays, cohort screening, and follow-up confirmation after discovery-stage sequencing. They also align with routine laboratory infrastructure, enabling faster scaling without major capital upgrades. As translational programs expand, demand for robust, high-throughput qPCR-based validation continues to rise.

The pharmaceutical & biotechnology companies segment dominated the market in 2024.

By end users for services, the market has been segmented into academic and research institutes, pharmaceutical and biotechnology companies, and hospitals and clinics. The pharmaceutical and biotechnology companies segment accounts for the largest share in 2024, driven by high spending on discovery and translational research. They use epigenetics tools and services to support target identification, mechanism-of-action studies, and biomarker development for clinical trials. Many programs also rely on external service providers for profiling and analytics to accelerate timelines and manage internal capacity. This consistent R&D demand sustains high-volume purchasing and long-term partnerships.   

Germany is expected to be the fastest-growing region in the Europe epigenetics market during the forecast period.

By country, the European epigenetics market is divided into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany holds the largest share and is growing at the fastest rate, supported by a strong pharmaceutical and biotech base and a dense network of research institutes and university hospitals. The country has established genomics infrastructure and core facilities that enable large-scale epigenetics studies. Germany’s active translational oncology ecosystem further drives demand for validation, profiling, and data interpretation. Ongoing research collaborations and funding programs continue to reinforce its growth momentum.

Key companies in the Europe epigenetics market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), QIAGEN (Germany), along with other regional and global companies.   

Don’t miss out on business opportunities in Europe Epigenetics Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/